

24th January, 2020

(1) BSE Ltd.
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

(2) National Stock Exchange of India Ltd.
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA

(3) SOCIETE DE LA BOURSE DE
LUXEMBERG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: USFDA cGMP inspection completed at Cipla's API manufacturing facility in Bommasandra, Bangalore

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the United States Food and Drug Administration ('USFDA') conducted a cGMP inspection at our API manufacturing facility in Bommasandra, Bangalore from 20th January, 2020 to 24th January, 2020.

The inspection ended with 4 observations which were procedural in nature and none of which were repeat or related to data integrity. The Company is committed to address these observations and will submit its response to the USFDA within the stipulated time

Kindly take the above information on record

Thanking you,

Yours faithfully

For Cipla Limited



Rajendra Chopra

Company Secretary

Prepared by: Juzer Masta